The overall survival (OS) analysis showed no statistically significant differences in OS among patients with TLR3 rs5743305 AA genotype and the TLR3 rs5743305 AT and TT genotypes—in the group with infections during AML treatment or in the group without infections (p-value, 0.711 and 0.465, respectively), Figure 5 and Figure 6. This evidence concerns the gene TLR3 and infection.